Topical Agent for Treatment of Red Skin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00279890
Recruitment Status : Completed
First Posted : January 20, 2006
Last Update Posted : May 23, 2011
Information provided by:
Mayo Clinic

Brief Summary:
SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety

Condition or disease Intervention/treatment Phase
Rosacea Bilaterally Symmetric Red Skin on Cheeks Drug: Topical SR-01 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Proof of Concept Trial:SR-01 for the Treatment of Rosacea
Study Start Date : July 2005
Primary Completion Date : January 2007
Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rosacea
U.S. FDA Resources

Primary Outcome Measures :
  1. Reduction of redness

Secondary Outcome Measures :
  1. Safety and tolerability
  2. Cosmetic acceptability

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Bilaterally symmetric red skin on cheeks Caucasian Age 18-60 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00279890

United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 55259
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Mark V. Dahl, M.D. Mayo Clinic

Responsible Party: Mark V. Dahl, M.D., Mayo Clinic Identifier: NCT00279890     History of Changes
Other Study ID Numbers: 44-05
MCS 385
First Posted: January 20, 2006    Key Record Dates
Last Update Posted: May 23, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Skin Diseases